These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 12461074)

  • 1. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate: reply by the authors.
    Crook M; Lynas J; Wray R
    J Clin Pathol; 2002 Dec; 55(12):976. PubMed ID: 12461074
    [No Abstract]   [Full Text] [Related]  

  • 2. A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.
    Crook MA; Lynas J; Wray R
    J Clin Pathol; 2000 Oct; 53(10):796-7. PubMed ID: 11064678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.
    Olukoga AO
    J Clin Pathol; 2002 Sep; 55(9):718. PubMed ID: 12195008
    [No Abstract]   [Full Text] [Related]  

  • 4. Paradoxical high-density lipoprotein reduction induced by fibrate therapy.
    Oleesky DA; Mir MA
    Ann Clin Biochem; 1997 Sep; 34 ( Pt 5)():573-4. PubMed ID: 9293321
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.
    Senba H; Kawano M; Kawakami M
    J Atheroscler Thromb; 2006 Oct; 13(5):263-4. PubMed ID: 17146155
    [No Abstract]   [Full Text] [Related]  

  • 6. Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice.
    Inaba T; Yagyu H; Itabashi N; Tazoe F; Fujita N; Nagashima S; Okada K; Okazaki M; Furukawa Y; Ishibashi S
    Hypertens Res; 2008 May; 31(5):999-1005. PubMed ID: 18712055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.
    Kawashiri MA; Kobayashi J; Nohara A; Noguchi T; Tada H; Nakanishi C; Inazu A; Mabuchi H; Yamagishi M
    Clin Chim Acta; 2011 May; 412(11-12):1068-75. PubMed ID: 21354122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL; Barradell LB; Plosker GL
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes.
    Hossain MA; Tsujita M; Gonzalez FJ; Yokoyama S
    J Cardiovasc Pharmacol; 2008 Mar; 51(3):258-66. PubMed ID: 18356690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
    Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
    Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
    Fruchart JC; Duriez P
    Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver.
    Roglans N; Bellido A; Rodríguez C; Cabrero A; Novell F; Ros E; Zambón D; Laguna JC
    Clin Pharmacol Ther; 2002 Dec; 72(6):692-701. PubMed ID: 12496750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes.
    Triolo M; Annema W; de Boer JF; Tietge UJ; Dullaart RP
    Eur J Clin Invest; 2014; 44(3):240-8. PubMed ID: 24325778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fenofibrate reverses the decline in HDL cholesterol in mice overexpressing human phospholipid transfer protein.
    Lie J; Lankhuizen IM; Gross B; van Gent T; van Haperen R; Scheek L; Staels B; de Crom R; van Tol A
    Biochim Biophys Acta; 2005 Dec; 1738(1-3):48-53. PubMed ID: 16298159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrate prevents cisplatin-induced proximal tubule cell death.
    Nagothu KK; Bhatt R; Kaushal GP; Portilla D
    Kidney Int; 2005 Dec; 68(6):2680-93. PubMed ID: 16316343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Overviews of fibrate].
    Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
    [No Abstract]   [Full Text] [Related]  

  • 17. [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
    Im M; Kim M; Lee JK; Chang YH; Lee DY; Hong SI; Lee YY; Hong YJ
    Korean J Lab Med; 2010 Feb; 30(1):17-9. PubMed ID: 20197717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential associations of statin and fibrate treatment with carotid arterial remodeling.
    Chironi G; Simon A; Gariepy J; Balice M; Del-Pino M; Levenson J
    Am J Hypertens; 2005 Nov; 18(11):1476-81. PubMed ID: 16280285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies.
    Rosenblat M; Ward S; Volkova N; Hayek T; Aviram M
    Biofactors; 2012; 38(4):292-9. PubMed ID: 22674772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of endothelial function in patients with metabolic syndrome on bezafibrate or atorvastatin therapy.
    Hanefeld C; Bulut-Streich N; Bulut D; Graf C; Mügge A; Spiecker M
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):153-5. PubMed ID: 16025235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.